Mod GRF 1-29 SPECIFICATIONS
AKA: Modified GRF (1-29)
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.95 g/mol
PubChem: CID 56841945
CAS Number: 863288-34-0
What is Mod GRF (1-29) Peptide?
Mod GRF (1-29) is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It was first developed in the 1980s when studies revealed that the first 29 amino acids of GHRH possessed all of the biological roles associated with the full-length 44 residue protein. The initially designed peptide, known as GRF (1-29), is the shortest segment of GHRH, which has all the properties of the full-length hormone. A different truncated synthetic form of GHRH known as Sermorelin or GRF 1-29 also has 29 amino acids.
Modified GRF (1-29) undergoes alteration to include four substituted amino groups in its chain. These amino modifications protect the peptide from both oxidation and degradation during manufacture and transport and in vivo. The modification further increases the binding affinity to GHRH receptors.
Though GRF happens to be biologically potent like GHRH, the duration of action is restricted due to a short half-life (less than 10 minutes). As a result, researchers have modified it to enhance its half-life with better therapeutic potential. Modified GRF (1-29), also known as, mod GRF or tetra-substituted GRF (1-29). The latter name clarifies that the modified peptide differs from GRF (1-29) as a result of changes in four of its amino acids. Modified GRF (1-29) is identical to CJC-1295 without DAC.
Modified GRF mediates the same biological effects as GHRH, including muscle growth (hypertrophy), improved bone development, enhanced lipolysis, accelerated metabolism, and wound healing. It also exhibits a positive influence on the immune system and blood sugar regulation.
Modified GRF (1-29) and Cardiac Function
Research in rodent models has highlighted that modified GRF and other GHRH derivatives can improve the capacity of the heart to pump blood even after a heart attack. This could be of immense potential in improving the quality of life and reducing death over the long term in patients diagnosed with cardiac failure. Modified GRF can be effective in treating pulmonary hypertension, cardiac failure, heart attack, and diverse congenital heart conditions.
Mod GRF (1-29) and the Intestine
Early studies have highlighted that growth hormone (GH) is beneficial for Crohn’s disease, short bowel syndrome, and other inflammatory bowel conditions. Unfortunately, the adverse effects of long-term use exceed the benefits of the hormone. Thus, researchers have looked into GHRH analogs for mediating a similar effect. Research in monkeys indicates that mod GRF binds with vasoactive intestinal peptide (VIP) receptors and improves bowel motility, as improved bowel movement is of crucial relevance in inflammatory bowel diseases associated with constipation. The peptide happens to interact with VIPC1, present on the smooth muscle of the reproductive, gastrointestinal as well as urinary systems. These conditions trigger a great deal of morbidity and are difficult to address due to the lack of alternative drug options.
The Interaction between Thyroid Hormone and Growth Hormone
Malfunctioning of the thyroid gland is often associated with concomitant issues in GH release. Patients suffering from hypothyroidism have been treated with modified GF to prove the above hypothesis. It has been observed that individuals who receive the thyroid replacement hormone demonstrate stronger reactions to GRF, proving a link between thyroid hormone and GH. Thus, peptides like modified GRF may contribute towards a better understanding of human physiology.
Modified GRF exhibits milder side effects, low oral bioavailability, and excellent subcutaneous bioavailability in mice. The dosage required in mice (per kg) does not scale to that suitable for humans.